THINPAD

Prof. Maurizio Botta

Scientific Coordinator of THINPAD, based at the University of Siena, Italy

Research field

Virology

If you like this
If you want to know more
Research Profile

Who?

Professor Botta observes the world through the eyes of a chemist. "I believe that everything is made of molecules", he says, "and my belief is that organic molecules are the key to developing a therapy against infectious diseases such as AIDS". His team is searching for molecules to fight HIV and anti-HIV drug resistance.

Why?

AIDS is one of the most serious pandemic diseases of the modern era. Therapies based on the interruption of the HIV replication cycle exist, but these therapies fail increasingly often due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies.

What?

The objective of THINPAD is to discover innovative anti-HIV agents. Professor Botta: “We develop drugs that target a protein in the shell of HIV. This protein is essential for HIV replication, so it is the Achilles' heel of the virus. We expect that HIV cannot become resistant to drugs that target this essential protein.”

How?

The THINPAD consortium brings together five teams at the forefront of HIV research. The teams are made up of two small to medium-sized enterprises in the fields of molecular biology and pharmaceutics and three academic research groups, including hospitals. The teams are located in three different EU member states.

Attacking the shell of HIV to fight drug resistance

In the Picture
In the Picture
Image credits

Background image: C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus, CDC

Portrait of the project coordinator: THINPAD

Timeline (in chronological order): 1983: C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus, CDC; 1996: Elizabeth Glaser Pediatric AIDS Foundation; 2012: worldaidsday.org